EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.

View source ↗

Summary

The EMA authorises Yescarta (axicabtagene ciloleucel) for certain lymphomas, indicating market authorization and orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Follicular;Lymphoma, Large B-Cell, Diffuse. MAH: Kite Pharma EU B.V.. Decision date: 08/06/2026. Orphan medicine